232 related articles for article (PubMed ID: 34654798)
1. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.
Rampioni Vinciguerra GL; Dall'Acqua A; Segatto I; Mattevi MC; Russo F; Favero A; Cirombella R; Mungo G; Viotto D; Karimbayli J; Pesce M; Vecchione A; Belletti B; Baldassarre G
Cell Death Dis; 2021 Oct; 12(10):951. PubMed ID: 34654798
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
3. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
4. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Pack LR; Daigh LH; Chung M; Meyer T
Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
[TBL] [Abstract][Full Text] [Related]
5. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
6. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
10. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
15. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4.
Larrea MD; Liang J; Da Silva T; Hong F; Shao SH; Han K; Dumont D; Slingerland JM
Mol Cell Biol; 2008 Oct; 28(20):6462-72. PubMed ID: 18710949
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture.
Gottesman SRS; Somma J; Tsiperson V; Dresner L; Govindarajulu U; Patel P; Blain SW
Mol Cancer Res; 2019 Mar; 17(3):669-675. PubMed ID: 30559257
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer.
Harada M; Morikawa M; Ozawa T; Kobayashi M; Tamura Y; Takahashi K; Tanabe M; Tada K; Seto Y; Miyazono K; Koinuma D
Cancer Sci; 2019 Jan; 110(1):209-220. PubMed ID: 30343527
[TBL] [Abstract][Full Text] [Related]
19. Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Nomanbhoy TK; Sharma G; Brown H; Wu J; Aban A; Vogeti S; Alemayehu S; Sykes M; Rosenblum JS; Kozarich JW
Biochemistry; 2016 Sep; 55(38):5434-41. PubMed ID: 27571378
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
Ziemke EK; Dosch JS; Maust JD; Shettigar A; Sen A; Welling TH; Hardiman KM; Sebolt-Leopold JS
Clin Cancer Res; 2016 Jan; 22(2):405-14. PubMed ID: 26369631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]